CClinicalTrials.gg
Active, not recruitingNCT06630988HandInfUpdated Oct 8, 2024

Diagnostic and Management of Hand Infection.

An observational study in Hand Infections, Including Whitlows and Tendinous Infections, sponsored by Hospices Civils de Lyon. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Hospices Civils de Lyon · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,400
Ages
18 Years and older
Sex
All
01

Study summary

Primary or secondary (post-traumatic infections, notably related to bites, wounds, etc.) infections of the hand are very common situations, even if the epidemiology is poorly understood. For example, hand bite injuries represent 1.2 million referrals to the healthcare system per year in the United States. Their nosological framework extends from simple infections of the skin and soft tissues such as whitlows, to potentially severe deep damage such as arthritis and osteitis, or phlegmons of the tendon sheaths. The diagnostic approach is not consensual, and the contribution of additional biological parameters (inflammatory syndrome) and morphological investigations (x-rays, ultrasound, CT-scan or MRI) is not codified. Microbiology seems dominated by Staphylococcus aureus, but few studies have precisely described the microbial etiology. Consequently, probabilistic antibiotic therapy and the need to take bacteriological samples for secondary adaptation are not standardized. Likewise, surgical strategies (abstention, systematic washing or depending on evolution) remain operator dependent. We consequently aim to described diagnostic, management and related outcomes or hand infections in a specialized tertiary care center.

02

Conditions studied

  • Hand Infections
  • Including Whitlows
  • Tendinous Infections
  • Septic Arthritis

Keywords

  • Hand infection
  • Whitlows
  • Tendinous infections
  • Septic arthritis
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 1,400 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be selected from the data base of the hand emergency surgery department of our tertiary care center, based on a principal or secondary diagnosis of BJI appearing alone or in combination with either sepsis or a specific surgical procedure - 1400 potential patients.

Inclusion criteria

  • all patient ≥ 18
  • yo followed-up for a hand infection in our tertiary care center
  • from 01/01/2014 to 31/12/2023, including
  • whitlows
  • tendinous infections
  • septic arthritis

Exclusion criteria

Exclusion Criteria:

  • osteomyelitis
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hand infection

    Description of whitlows, tendinous infections and septic arthritis diagnostic, management and outcome Descriptive study, no intervention

    Other: Failure rates

Interventions

  • OtherFailure rates

    Describe the management failure rate for hand infections, including panariasis, phlegmons and arthritis.

06

What researchers measure

Primary outcomes

  1. Percentage of treatment failure during the management of hand infections.

    Treatment failure will be defined as infection persistence or relapse, need of unplanned surgery for septic reason or infection-related death.

    Time frame: between 01/01/2014 and 31/12/2023.

07

Study locations

1 site
  • HCL - Hôpital Edouard Herriot
    Lyon, 69003, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06630988
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Sep 1, 2024
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Oct 8, 2024

Study contacts

Florent Valour Pr Florent Valour, Pr
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion